Clinical trials: Stem Cell Transplant
Acute Leukemia, Hematologic and Lymphocytic Disorder
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
This phase IIa trial studies the side effects of itacitinib when given together with standard treatment (tacrolimus and sirolimus), and to see how well it works in preventing graft-versus-host-disease (GVHD) in patients with…
- Conditions
- Acute Leukemia, Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome, Primary Myelofibrosis
- Trial name
- NCT04339101
- Testing
- Fludarabine, Itacitinib Adipate, Melphalan
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
RATIONALE: Giving low doses of chemotherapy, such as busulfan and fludarabine, before a donor stem cell transplant helps stop the growth of cancer and abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00448201
- Testing
- anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Osteopenia, Osteoporosis
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
This is a Phase 2, open-label, randomized, controlled clinical study of pediatric subjects treated with pamidronate with calcium and vitamin D versus calcium and vitamin D alone following hematopoietic cell transplantation (HCT).
- Trial name
- NCT02074631
- Testing
- Pamidronate, Calcium and vitamin D
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS
This study compares the safety and effectiveness of giving rivogenlecleucel (BPX-501 T cells) to patients with AML or MDS post haploidentical hematopoietic stem cell transplant compared to post-transplant cyclophosphamide.
- Trial name
- THRIVE (NCT03699475)
- Testing
- rivogenlecleucel, rimiducid, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Bellicum Pharmaceuticals
Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as…
- Conditions
- Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis
- Trial name
- NCT01849783
- Testing
- dexamethasone, cisplatin, doxorubicin
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Margarida Magalhaes-Silverman
Lymphoma, Small Intestine Cancer
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma
RATIONALE: Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, and may stimulate the immune system to stop cancer cells from growing.
- Trial name
- NCT00561418
- Testing
- vorinostat, Correlative studies
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Sickle Cell Disease, Thalassemia Major
Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies
This is a single arm pilot study of peripheral stem cell transplantation (PSCT) with ex vivo t-cell receptor alpha beta+(TCRαβ+) T cell and cluster of differentiation 19+ beta (CD19+ B) cell depletion of unrelated donor (URD)…
- Trial name
- NCT04523376
- Testing
- CliniMACS
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Timothy Olson
Mucopolysaccharidosis I, Mucopolysaccharidosis VI
Stem Cell Transplantation for Hurler
The purpose of this study is to determine the safety and engraftment of donor hematopoietic cells using this conditioning regimen in patients undergoing a hematopoietic (blood forming) cell transplant for Hurler syndrome…
- Conditions
- Mucopolysaccharidosis I, Mucopolysaccharidosis VI, Mannosidosis, Mucolipidosis Type II (I-cell Disease)
- Trial name
- NCT00176917
- Testing
- Stem Cell Transplant, Busulfan, Cyclophosphamide, ATG
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn what dose of a kind of immune cell called T-lymphocytes (T-cells) given as a donor infusion about 8-9 weeks after a stem cell transplant has the best results.
- Conditions
- Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01518153
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Non-Hodgkins Lymphoma
Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant
Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients.
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma, Hodgkins Disease
- Trial name
- NCT00901225
- Testing
- G-CSF plus Plerixafor
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Duke University
Multiple Myeloma
Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
This study is for patients that have multiple myeloma that has come back or relapsed and their condition indicates a procedure called an Autologous Hematopoietic Stem Cell Transplantation (AHSCT).
- Trial name
- NCT01690143
- Testing
- Carfilzomib, Melphalan
- Where
- 4 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Alabama at Birmingham
Herpes Zoster
Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A
The purpose of this observer-blind study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' investigational Herpes Zoster vaccine GSK1437173A when administered as 2 doses or 3 doses to hematopoietic stem…
- Trial name
- NCT00920218
- Testing
- Herpes Zoster Vaccine 1437173A
- Where
- 11 sites in United States
- Volunteers
- 121 people
- Sponsor
- GlaxoSmithKline
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia
Allogeneic Stem Cell Transplant for CLL
This phase I/II trial studies the best dose and side effects of gemcitabine and how well it works with clofarabine and busulfan and donor stem cell transplant in treating participants with chronic lymphocytic leukemia.
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Richter Syndrome
- Trial name
- NCT01629511
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Busulfan
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Acute Myelogenous Leukemia
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
RATIONALE: Giving chemotherapy, such as fludarabine phosphate and cyclophosphamide, and total body irradiation, before peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00303667
- Testing
- aldesleukin, natural killer cells, cyclophosphamide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor
The purpose of this study is to determine whether ATIR is safe and effective in reducing transplant-related mortality and improving overall survival, when infused in patients with a hematologic malignancy following a T-cell…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01794299
- Testing
- ATIR
- Where
- 8 sites in Belgium, Canada and 2 more
- Volunteers
- 31 people
- Sponsor
- Kiadis Pharma
Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation
Maraviroc in Patients Undergoing Non-Myeloablative Allogeneic Stem-Cell Transplantation
This study investigates the effectiveness and safety of Maraviroc (an oral medication given twice daily given in addition to the standard GVHD prophylaxis) in preventing Graft versus Host Disease (GVHD) in patients undergoing…
- Trial name
- NCT00948753
- Testing
- Maraviroc 150 MG, Maraviroc 300 mg, Maraviroc 300 mg Phase II
- Volunteers
- 38 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor
The primary hypothesis of this research study is that patients in remission undergoing myeloablative haploidentical hematopoietic stem cell transplantation (HSCT) on the Thomas Jefferson University (TJU) 2 Step treatment regimen…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Biphenotypic Leukemia, Acute Lymphocytic Leukemia
- Trial name
- NCT01350245
- Testing
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Hematological Malignancies
Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings
The present project aims at comparing two nonmyeloablative regimens currently used in 2 major HCT centers in the US for patients with HLA-matched related or unrelated donor: the one from the Seattle group consisting of 2 Gy TBI…
- Trial name
- NCT00603954
- Testing
- Conditioning regimen: TBI + Fludarabine, Conditioning regimen:TLI (8 Gy) + ATG
- Where
- 11 sites in Belgium, Netherlands
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Liege
Inherited Metabolic Disorders (IMD)
MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
This study is designed to assess the safety and efficacy of using MGTA-456 in patients with Inherited Metabolic Disorders (IMD) undergoing stem cell transplantation.
- Trial name
- NCT03406962
- Testing
- MGTA-456
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Magenta Therapeutics, Inc.
Hematological Malignancy
Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
The purpose of this study is to determine if Bortezomib, known commercially as Velcade is safe and tolerated at different dose levels (amounts) with high dose Cyclophosphamide to be used as graft versus host disease prevention…
- Trial name
- NCT01860170
- Testing
- Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®)
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Corewell Health West
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.